Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This pilot phase II trial studies how well selumetinib works in treating patients with
neurofibromatosis type 1 and cutaneous neurofibromas. Selumetinib may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth.